IDL-2965

Status
Phase 1
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

IDL-2965, is an oral, selective RGD-binding integrin antagonist of avb1, avb3, and avb6 that uniquely inhibits multiple processes of pathologic fibrosis, including the local activation of TGF-b by both epithelial cells and fibroblasts, as well as the ability of stiff extracellular matrix to promote fibroblast migration and survival.

Study Purpose

The purpose of this study is to test the safety and tolerability of the drug candidate IDL-2965 and to see how it is absorbed, processed, and removed by the body.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >